July - September 2015, Volume 11, Issue 3

Galoiu S

Replacement Therapy with Recombinant Parathyroid Hormone (1-84) in Hypoparathyroidism

Acta Endo (Buc) 2015, 11 (3): 413-414
doi: 10.4183/aeb.2015.413

Hypoparathyroidism is a disease characterized by low serum calcium and inappropriate low parathyroid hormone (PTH) levels. Common therapy for chronic hypoparathyroidism usually includes oral calcium and activated vitamin D supplementation (calcitriol), hypoparathyroidism being the one of few endocrine disorders not replaced by the missing hormone. In January 2015, FDA approved PTH (1-84) for the treatment of hypoparathyroidism in patients who cannot be well-controlled on calcium and active forms of vitamin D alone and for whom the potential benefits are considered to outweigh this potential risk. Until now, there are 4 phase 3 clinical trials investigating the role of human recombinant PTH (1-84) for the treatment of hyopoparathyroidism: Replace, Race, Relay, and Repeat. These studies demonstrated a more than 50% reduction in calcium and active vitamin D requirements. Future strategies for the treatment of hypoparathyroidism could be stem cell therapy recombinant with PTH and viral or nonviral factors or parathyroid gland transplantation.

Keywords: PTH, hypoparathyroidism

Correspondence: Simona Galoiu MD, “Carol Davila” University of Medicine and Pharmacy, “C.I.Parhon” National Institute of Endocrinology, 34-36 Blvd Aviatorilor, Bucharest, 011863, Romania, E-mail: simona.galoiu@gmail.com